S&P 500   3,795.54
DOW   30,991.52
QQQ   314.35
S&P 500   3,795.54
DOW   30,991.52
QQQ   314.35
S&P 500   3,795.54
DOW   30,991.52
QQQ   314.35
S&P 500   3,795.54
DOW   30,991.52
QQQ   314.35
Log in
NASDAQ:VIR

Vir Biotechnology Stock Forecast, Price & News

$36.49
+0.94 (+2.64 %)
(As of 01/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$34.06
Now: $36.49
$36.54
50-Day Range
$26.34
MA: $29.21
$35.55
52-Week Range
$14.25
Now: $36.49
$75.00
Volume1.32 million shs
Average Volume1.45 million shs
Market Capitalization$4.65 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; a collaboration with WuXi Biologics; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.

MarketRank

Overall MarketRank

0.99 out of 5 stars

Analyst Opinion: 3.3Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VIR
CUSIPN/A
CIKN/A
Phone415-906-4324
Employees297

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$8.09 million
Book Value$3.87 per share

Profitability

Net Income$-174,680,000.00
Net Margins-293.64%

Miscellaneous

Market Cap$4.65 billion
Next Earnings Date3/25/2021 (Estimated)
OptionableOptionable
$36.49
+0.94 (+2.64 %)
(As of 01/14/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VIR News and Ratings via Email

Sign-up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Vir Biotechnology (NASDAQ:VIR) Frequently Asked Questions

How has Vir Biotechnology's stock been impacted by Coronavirus (COVID-19)?

Vir Biotechnology's stock was trading at $33.77 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, VIR shares have increased by 8.1% and is now trading at $36.49.
View which stocks have been most impacted by COVID-19
.

Is Vir Biotechnology a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vir Biotechnology in the last twelve months. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Vir Biotechnology stock.
View analyst ratings for Vir Biotechnology
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Vir Biotechnology?

Wall Street analysts have given Vir Biotechnology a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Vir Biotechnology wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Vir Biotechnology's next earnings date?

Vir Biotechnology is scheduled to release its next quarterly earnings announcement on Thursday, March 25th 2021.
View our earnings forecast for Vir Biotechnology
.

How were Vir Biotechnology's earnings last quarter?

Vir Biotechnology, Inc. (NASDAQ:VIR) released its quarterly earnings results on Tuesday, November, 10th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.57) by $0.10. The company earned $1.93 million during the quarter, compared to analysts' expectations of $2.65 million. Vir Biotechnology had a negative return on equity of 81.12% and a negative net margin of 293.64%.
View Vir Biotechnology's earnings history
.

What price target have analysts set for VIR?

7 Wall Street analysts have issued twelve-month target prices for Vir Biotechnology's shares. Their forecasts range from $24.00 to $100.00. On average, they anticipate Vir Biotechnology's share price to reach $55.00 in the next year. This suggests a possible upside of 50.7% from the stock's current price.
View analysts' price targets for Vir Biotechnology
or view Wall Street analyst' top-rated stocks.

Who are some of Vir Biotechnology's key competitors?

Who are Vir Biotechnology's key executives?

Vir Biotechnology's management team includes the following people:
  • Dr. George A. Scangos, Pres, CEO & Director (Age 73, Pay $785.83k)
  • Dr. Klaus Frueh, Co-Founder & Scientific Advisor (Age 61, Pay $177.66k)
  • Mr. Howard Horn, CFO & Sec. (Age 44, Pay $599.25k)
  • Dr. Herbert W. Virgin IV, Exec. VP of Research & Chief Scientific Officer (Age 65, Pay $949.9k)
  • Dr. Jay Parrish, Co-Founder & Chief Bus. Officer (Age 46)
  • Dr. Lawrence Corey, Co-Founder & Scientific Advisor
  • Dr. Louis J. Picker, Co-Founder & Scientific Advisor
  • Dr. Michael E. Kamarck, Chief Technology Officer (Age 70)
  • Mr. Steven J. Rice, Chief Admin. Officer
  • Dr. Neera Dahiya Ravindran M.D., MBA, VP and Head of Investor Relations & Strategic Communications

When did Vir Biotechnology IPO?

(VIR) raised $149 million in an initial public offering (IPO) on Friday, October 11th 2019. The company issued 7,100,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Barclays served as the underwriters for the IPO.

What is Vir Biotechnology's stock symbol?

Vir Biotechnology trades on the NASDAQ under the ticker symbol "VIR."

How do I buy shares of Vir Biotechnology?

Shares of VIR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Vir Biotechnology's stock price today?

One share of VIR stock can currently be purchased for approximately $36.49.

How big of a company is Vir Biotechnology?

Vir Biotechnology has a market capitalization of $4.65 billion and generates $8.09 million in revenue each year. The company earns $-174,680,000.00 in net income (profit) each year or ($5.76) on an earnings per share basis. Vir Biotechnology employs 297 workers across the globe.

What is Vir Biotechnology's official website?

The official website for Vir Biotechnology is www.vir.bio.

How can I contact Vir Biotechnology?

Vir Biotechnology's mailing address is 499 ILLINOIS STREET SUITE 500, SAN FRANCISCO CA, 94158. The company can be reached via phone at 415-906-4324 or via email at [email protected]

This page was last updated on 1/15/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.